This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Danova M, Chiroli S, Rosti G, Doan QV.Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients. Tumori 95: 219-226, No. 2, Mar-Apr 2009
Rights and permissions
About this article
Cite this article
Pegfilgrastim more cost effective than filgrastim in breast cancer. Pharmacoecon. Outcomes News 587, 4 (2009). https://doi.org/10.2165/00151234-200905870-00011
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905870-00011